Health
15 Oct 2026
Arrowhead's RNAi drug reduces Alzheimer’s‑linked tau protein in early trials
In an early safety study, Arrowhead Pharmaceuticals’ ARO‑MAPT lowered brain‑related tau protein by up to 85% in healthy volunteers, suggesting potential for Alzheimer’s treatment.
Read more